Background: Hidradenitis suppurativa (HS) is a long-term skin disorder associated with high levels of psychological distress and significant life impact. Objective: To evaluate the quality of life, depression, anxiety, loneliness, and self-esteem in patients with HS. Methods: Ninety-four patients with HS were enrolled in the study. The quality of life, depression, anxiety, loneliness, and self-esteem of the patients were assessed using the Dermatology Life Quality Index (DLQI), the Hospital Anxiety and Depression Scale (HADS), the UCLA Loneliness Scale (UCLA-Version 3), and the Rosenberg Self-Esteem Scale (RSES), respectively. Results: The DLQI mean score was 11.43 ± 6.61 in patients with HS. The patients with HS presented statistically significantly higher anxiety (6.41 ± 3.31 vs. 5.00 ± 1.59, p < 0.001), depression (5.45 ± 2.79 vs. 4.16 ± 1.54, p < 0.001), and loneliness and social isolation scores (42.86 ± 8.63 vs. 35.57 ± 6.17, p < 0.001) and lower self-esteem scores (18.91 ± 1.79 vs. 19.77 ± 2.53, p = 0.008) than the healthy controls. Conclusions: HS is a distressing, recurrent disease that impairs quality of life. We can suggest services that allow an integrated approach, which includes psychosocial support, offering the patients relief from isolation and an opportunity to share common experiences.

1.
Zouboulis CC, Del Marmol V, Mrowietz U, Prens EP, Tzellos T, Jemec GB: Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 2015;231:184-190.
2.
Jemec GB: Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012;366:158-164.
3.
Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GB: European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015;29:619-644.
4.
Micheletti RG: Hidradenitis suppurativa: current views on epidemiology, pathogenesis, and pathophysiology. Semin Cutan Med Surg 2014;33:48-50.
5.
Matusiak L, Bieniek A, Szepietowski JC: Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 2010;62:706-708.
6.
von der Werth JM, Jemec GB: Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001;144:809-813.
7.
Hurley HJ: Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach; in Roenigk RK, Roenigk HH (eds): Dermatologic Surgery. New York, Marcel Dekker, 1989, pp 729-739.
8.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin and Exp Dermatol 1994;19:210-216.
9.
Zigmond AS, Snaith RP: The Hospital anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-370.
10.
Michopoulos I, Douzenis A, Kalkavoura C, Christodoulou C, et al: Hospital Anxiety and Depression Scale (HADS): validation in a Greek general hospital sample. Ann Gen Psychiatry 2008;7:4.
11.
Russel DW: UCLA Loneliness Scale (Version 3): Reliability, validity and factor structure. J Pers Assess 1996;66:20-40.
12.
Kafetsios K: Adult attachment, coping with stress and social support as predictors of mental health. Comparative results from Greece and the UK. Abstracts of the International Conference in Personal Relationships, University of Queensland, Australia 2000, pp 38-39.
13.
Rosenberg M: Society and the Adolescent Self-image. Princenton, Princeton University Press, 1965.
14.
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY: Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005;125:659-664.
15.
Vinding GR, Knudsen KM, Ellervik C, Olesen AB, Jemec GB: Self-reported skin morbidities and health-related quality of life: a population-based nested case-control study. Dermatology 2014;228:261-268.
16.
Matusiak L, Bieniek A, Szepietowski JC: Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010;90:264-268.
17.
Alavi A, Anooshirvani N, Kim WB, Coutts P, Sibbald RG: Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study. Am J Clin Dermatol 2015;16:61-65.
18.
Smith HS, Chao JD, Teitelbaum J: Painful hidradenitis suppurativa. Clin J Pain 2010;26:435-444.
19.
Esmann S, Jemec GB: Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011;91:328-332.
20.
Janse IC, Deckers IE, van der Maten AD, Evers AW, Boer J, van der Zee HH, Prens EP, Horváth B: Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicenter cross-sectional study. Br J Dermatol 2016, DOI: 10.1111/bjd.14975, Epub ahead of print.
21.
Kurek A, Peters EM, Chanwangpong A, Sabat R, Sterry W, Schneider-Burrus S: Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol 2012;67:422-428.
22.
Deckers IE, Kimball AB: The handicap of hidradenitis suppurativa. Dermatol Clin 2016;34:17-22.
23.
Jemec GB, Heidenheim M, Nielsen NH: Hidradenitis suppurativa: characteristics and consequences. Clin Exp Dermatol 1996;21:419-423.
24.
Matusiak L, Bieniek A, Szepietowski JC: Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010;90:264-268.
25.
Onderdijk AJ, van der Zee HH, Esmann S, Lophaven S, Dufour DN, Jemec GB, Boer J: Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013;27:473-478.
26.
Kurek A, Johanne Peters EM, Sabat R, Sterry W, Schneider-Burrus S: Depression is a frequent co-morbidity in patients with acne inversa. J Dtsch Dermatol Ges 2013;11:743-750.
27.
Kromann CB, Deckers IE, Esmann S, Boer J, Prens EP, Jemec GB: Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol 2014;171:819-824.
28.
Sartorius K, Emtestam L, Jemec GB, Lapins J: Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009;161:831-839.
29.
Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD: Psychiatric comorbidities in 3,207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2015;29:371-376.
30.
Gooderham M, Papp K: The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol 2015;73:19-22.
31.
Joachim G, Acorn S: Stigma of visible and invisible chronic conditions. J Adv Nurs 2000;32:243-248.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.